Invesco ltd: Form 8.3 - Horizon Therapeutics plc

FORM 8.3

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVERRULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.      KEY INFORMATION

(a)   Full name of discloser Invesco Ltd.
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offeree Horizon Therapeutics PLC
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)  
(e)   Date position held/dealing undertaken For an opening position disclosure, state the latest practicable date prior to the disclosure 08/12/2022
(f)   In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” N/A

2.      INTERESTS AND SHORT POSITIONS

If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) (Note 2)

Class of relevant security (Note 3) Common Stock IE00BQPVQZ61
  Interests Short positions
Number % Number %
(1)   Relevant securities owned and/or controlled 3,512,263 1.549    
(2)   Cash-settled derivatives        
(3)   Stock-settled derivatives (including options) and agreements to purchase/ sell        
Total 3,512,263 1.549    

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3.      DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.The currency of all prices and other monetary amounts should be stated.

(a)      Purchases and sales

Class of relevantsecurity Purchase/sale Number ofsecurities Price per unit(Note 5)
Common Stock Purchase 63 96.91 USD
Common Stock Purchase 11 96.55 USD
       
       

(b)      Cash-settled derivative transactions

Class ofrelevantsecurity Product description e.g. CFD Nature of dealinge.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position Number ofreference securities (Note 6) Price per unit (Note 5)
         

(c)      Stock-settled derivative transactions (including options)

(i)      Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates (Note 6) Exerciseprice per unit Type e.g. American, Europeanetc. Expiry date Option moneypaid/ received per unit
                

(ii)      Exercise

Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (Note 5)
          

(d)      Other dealings (including transactions in respect of new securities) (Note 3)

Class of relevant security Nature of dealing e.g. subscription, conversion, exercise Details Price per unit (if applicable) (Note 5)
       

4.      OTHER INFORMATION

(a)      Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer. Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
 

(b)      Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
 

(c)        Attachments

Is a Supplemental Form 8 attached? NO
Date of disclosure 09/12/2022
Contact name Philippa Holmes
Telephone number 01491 417447

Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

        

Invesco (LSE:0UAN)
過去 株価チャート
から 11 2024 まで 12 2024 Invescoのチャートをもっと見るにはこちらをクリック
Invesco (LSE:0UAN)
過去 株価チャート
から 12 2023 まで 12 2024 Invescoのチャートをもっと見るにはこちらをクリック